Comparison

MOTS-c vs
NAD+

They are different molecules, and the evidence around them is not interchangeable. Here is what the research and dated status checks can—and cannot—tell you.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

MOTS-c and NAD+ are different molecules: MOTS-c is a 16-amino-acid peptide encoded in mitochondrial 12S rRNA, while NAD+, nicotinamide adenine dinucleotide, is a coenzyme, not a peptide. MOTS-c has cell and animal studies; we found no published study that gave it to people (21 November 2026). Pooled trials of NAD+ and nicotinamide riboside found no main-outcome difference (2026).

Key takeaways

  • MOTS-c is a peptide; NAD+ is a coenzyme, not a peptide.
  • MOTS-c studies include cell and animal research; the human research cited here measured naturally occurring MOTS-c, not an administered peptide.
  • FDA’s compounding list (updated 14 May 2026) places NAD, the coenzyme, in Category 1, “Bulk Drug Substances Under Evaluation”.
  • WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1, prohibited at all times. Neither names the coenzyme NAD+; the List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

01MOTS-c vs NAD+ in one table

Status checks and evidence summarized as of 21 November 2026. Each status is what the named document or database shows on that date; none is a legal conclusion of ours.

QuestionMOTS-cNAD+
What it isA 16-amino-acid peptide encoded by a short open reading frame in mitochondrial 12S rRNA.Nicotinamide adenine dinucleotide, a coenzyme; not a peptide.
Evidence tierCell (T4) and animal (T3) studies, not evidence of an effect in people; human studies measured natural levels (T2).Human trials are small (T1), as graded on its guide; work in rodents is further along (T3), a 2021 review says.
Human dataA 2021 study measured naturally occurring MOTS-c in 10 sedentary men; it did not give MOTS-c. We found no published study that gave MOTS-c to people (PubMed and ClinicalTrials.gov, 21 Nov 2026).A 2026 analysis that pooled four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+. Studies of precursors are not studies of NAD+ itself.
United StatesFDA staff wrote that neither form is “a component of an FDA-approved drug” and recommended against adding MOTS-c to the 503A bulks list; HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c.FDA’s 503A list (updated 14 May 2026) places NAD in Category 1, “Bulk Drug Substances Under Evaluation”. Drugs@FDA lists no product containing nadide or nicotinamide adenine dinucleotide (openFDA, 21 Nov 2026).
United KingdomThe emc medicines database returned no results for MOTS-c (21 Nov 2026); it is not the full UK register.The emc database returned no results for nadide or nicotinamide adenine dinucleotide (21 Nov 2026); it is not the full UK register.
AustraliaThe TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our own.The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines (safety alert, last updated 3 Feb 2026). The Poisons Standard October 2026 does not name it; we draw no scheduling conclusion of our own.
SportNamed in WADA class S4.4.1, metabolic modulators, and prohibited at all times under both the 2026 and 2027 Lists.Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

02How are the molecules different?

If you searched “mots c vs nad”, start with identity. MOTS-c is a peptide sequence; NAD+ is a coenzyme. They are not two names for the same molecule, and a finding about one does not transfer to the other.

Peptide

MOTS-c

FDA describes MOTS-c as a 16-amino-acid peptide encoded within mitochondrial 12S rRNA.

Coenzyme

NAD+

Nicotinamide adenine dinucleotide is a different molecular class. It is not a peptide sequence.

Comparison limit

Separate evidence

A result about one molecule cannot establish a result about the other.

For MOTS-c, FDA’s briefing describes the peptide and its mitochondrial origin. For NAD+, the FDA compounding list uses the name “Nicotinamide Adenine Dinucleotide (NAD).” The names in those documents identify distinct substances; they do not make the substances interchangeable.

03What human research is described here?

The human evidence shown for MOTS-c is about naturally occurring levels, not administration of the peptide.

1
Human measurements

Reynolds and colleagues’ 2021 study measured naturally occurring MOTS-c in muscle and blood in 10 sedentary men, with a mean age of 24.5 years. This is T2 evidence about measured levels, not a trial of administered MOTS-c.

2
Cell and animal work

MOTS-c research also includes cell experiments and animal models. Those are T4 and T3 evidence tiers, respectively, and do not establish an effect in people.

3
Keep NAD+ studies specific

NAD+ has its own small trials (T1), graded on its guide. Before comparing a human study, identify whether it measured NAD+ itself or a precursor such as nicotinamide riboside.

For the MOTS-c research record and its limits, see the MOTS-c research guide. The studies summarized here do not provide a head-to-head comparison of MOTS-c and NAD+.

04What do the status checks show?

The table reports what the named documents say on the dates given, not a legal verdict for a reader or a particular material.

United States. FDA’s 503A list (updated 14 May 2026) places NAD in Category 1, which it labels “Bulk Drug Substances Under Evaluation”. For MOTS-c, FDA staff wrote that neither form is “a component of an FDA-approved drug” and recommended against adding it to the 503A bulks list; HHS records that its advisory committee voted in favour of both forms, and HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c. These are different statements about different regulatory questions.

United Kingdom and Australia. The UK emc database returned no results for MOTS-c, nadide or nicotinamide adenine dinucleotide (21 November 2026), and the Poisons Standard October 2026 names neither molecule. The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines. We draw no scheduling or legal conclusion of our own.

Sport. WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1. Neither names NAD+, NAD or nadide; the List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

For MOTS-c, FDA’s briefing also distinguishes MOTS-c free base from MOTS-c acetate as different bulk drug substances. To assess what a particular report identifies, read how to read a COA; a purity percentage alone does not distinguish MOTS-c from a different molecule.

05What we don’t know

  • How MOTS-c and NAD+ compare in people. The cited MOTS-c human study measured natural levels; it did not compare the two molecules.
  • Whether the small NAD+ trials say anything beyond the people and measures they studied.
  • How anti-doping organisations would apply the List’s classes to NAD+, which the List does not name.
  • What is in any particular vial. A report must identify the lot and provide a distinct identity result.

This is a plain-English summary of public documents and studies, checked on 21 November 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (PDF pp. 7, 9, 29, 31, 33); read 21 Nov 2026. www.fda.gov/media/193347/download
  2. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  3. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), Appendix B. Read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  4. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice, 91 FR 68526, 30 October 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  5. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109; full text PMC7817689 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/33473109/
  6. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459. pubmed.ncbi.nlm.nih.gov/25738459/
  7. PubMed search: MOTS-c names with randomisation, placebo, administration and human terms, no publication-type filter: 13 records, none giving MOTS-c to people (cell, animal and level-measurement studies, and reviews). Database search, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28%22MOTS-c%22%5Btiab%5D%20OR…
  8. ClinicalTrials.gov. NCT07505745 [registered MOTS-c trial: eligibility and status]. Registry record read through the ClinicalTrials.gov API, 21 Nov 2026; last update posted 1 Apr 2026; no results posted. clinicaltrials.gov/study/NCT07505745
  9. PubChem. Nadide (nicotinamide adenine dinucleotide), CID 5892. Compound record, read 21 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/5892
  10. Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. [Systematic review and meta-analysis of four randomised placebo-controlled trials of NAD+ or nicotinamide riboside.] Eur J Clin Pharmacol, 2026;82(12):295. PMID 43040090 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/43040090/
  11. U.S. Food and Drug Administration. Drugs@FDA data through openFDA: searches for nadide and nicotinamide adenine dinucleotide as active ingredients, no match (control, semaglutide: found). Database queries, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingred…
  12. Electronic medicines compendium (emc). Search for MOTS-c: “No search results” (control search, somatropin: 21 results). Database search, 21 Nov 2026. www.medicines.org.uk/emc/search?q=MOTS-c
  13. Electronic medicines compendium (emc). Searches for nadide and nicotinamide adenine dinucleotide: “No search results” (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=nadide
  14. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  15. Therapeutic Goods Administration. NAD, NAD+, NADH or NMN medicines sold in Australia. Safety alert, published 7 Apr 2025, last updated 3 Feb 2026; read on the Internet Archive capture of 18 Apr 2026, the newest available (tga.gov.au did not respond to our tools). web.archive.org/web/20260418171031/https://www.tga.gov.au/sa…
  16. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  17. World Anti-Doping Agency. Prohibited List 2026. International Standard, in force 1 January 2026; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  18. World Anti-Doping Agency. Prohibited List 2027. International Standard, in force 1 January 2027; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Are MOTS-c and NAD+ the same molecule?

No. MOTS-c is a 16-amino-acid peptide. NAD+ is nicotinamide adenine dinucleotide, a coenzyme.

Has MOTS-c been given to people in a published study?

The literature and registry checks cited here found no published study that gave MOTS-c to people as of 18 November 2026. The 2021 human study measured naturally occurring levels instead.

What does FDA’s Category 1 listing for NAD mean?

FDA labels Category 1 “Bulk Drug Substances Under Evaluation”: substances nominated for its 503A compounding list that it is still evaluating. NAD, the coenzyme, is in that category (list updated 14 May 2026).

Is MOTS-c prohibited in sport?

WADA’s 2026 Prohibited List names MOTS-c in S4.4.1, metabolic modulators, a class prohibited at all times.

Does WADA’s Prohibited List name NAD+?

No. Neither the 2026 nor the 2027 List names NAD+, NAD or nadide. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page